Evidence map›Paper›PMID 25978681›Full record

ArticlePloS one2015

Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions.

Andrii Dinets, Maria Pernemalm, Hanna Kjellin, Vitalijs Sviatoha, Anastasios Sofiadis, C Christofer Juhlin, Jan Zedenius, Catharina Larsson, Janne Lehtiö, Anders Höög

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Andrii DinetsDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Center Karolinska, Karolinska University Hospital, SE-171 76, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76, Stockholm, Sweden.
Maria PernemalmDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, SE-171 65, Stockholm, Sweden.
Hanna KjellinDepartment of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, SE-171 65, Stockholm, Sweden.
Vitalijs SviatohaDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Center Karolinska, Karolinska University Hospital, SE-171 76, Stockholm, Sweden; Department of Pathology-Cytology, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
Anastasios SofiadisDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Center Karolinska, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
C Christofer JuhlinDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Center Karolinska, Karolinska University Hospital, SE-171 76, Stockholm, Sweden; Department of Pathology-Cytology, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
Jan ZedeniusDepartment of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76, Stockholm, Sweden.
Catharina LarssonDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Center Karolinska, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
Janne LehtiöDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, SE-171 65, Stockholm, Sweden.
Anders HöögDepartment of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Cancer Center Karolinska, Karolinska University Hospital, SE-171 76, Stockholm, Sweden; Department of Pathology-Cytology, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
Karolinska University Hospital · SEKarolinska Institutet · SEScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic papillary thyroid carcinoma (cPTC) is a subgroup of PTC presenting a diagnostic challenge at fine needle aspiration biopsy (FNAB). To further investigate this entity we aimed to characterize protein profiles of cyst fluids from cPTC and benign thyroid cystic lesions. In total, 20 cPTCs and 56 benign thyroid cystic lesions were studied. Profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed on cyst fluids from a subset of cases after depletion, and selected proteins were further analyzed by Western blot (WB), immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA). A total of 1,581 proteins were detected in cyst fluids, of which 841 were quantified in all samples using LC-MS/MS. Proteins with different expression levels between cPTCs and benign lesions were identified by univariate analysis (41 proteins) and multivariate analysis (59 proteins in an orthogonal partial least squares model). WB analyses of cyst fluid and IHC on corresponding tissue samples confirmed a significant up-regulation of cytokeratin 19 (CK-19/CYFRA 21-1) and S100A13 in cPTC vs. benign lesions. These findings were further confirmed by ELISA in an extended material of non-depleted cyst fluids from cPTCs (n = 17) and benign lesions (n = 55) (p<0.05). Applying a cut-off at >55 ng/ml for CK-19 resulted in 82% specificity and sensitivity. For S100A13 a cut-off at >230 pg/ml revealed a 94% sensitivity, but only 35% specificity. This is the first comprehensive catalogue of the protein content in fluid from thyroid cysts. The up-regulations of CK-19 and S100A13 suggest their possible use in FNAB based preoperative diagnostics of cystic thyroid lesions.

Indexed as

TranscriptomeAdultAgedAged, 80 and overBlotting, WesternCarcinomaCarcinoma, PapillaryCystsEnzyme-Linked Immunosorbent AssayFemaleHumansIsoelectric FocusingMaleMiddle AgedTandem Mass SpectrometryThyroid Cancer, Papillary

Identifiers

PMID25978681
PMCPMC4433121
OpenAlexW273012573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.